Literature DB >> 30417341

Guideline-concordant initiation of oral anticoagulant therapy for stroke prevention in older veterans with atrial fibrillation eligible for Medicare Part D.

Nicolae Done1, Amanda M Roy2, Yingzhe Yuan3, Steven D Pizer4, Adam J Rose5, Julia C Prentice1.   

Abstract

OBJECTIVE: To characterize the rate of guideline-concordant initiation of oral anticoagulation (OAC) among elderly Veterans with atrial fibrillation (AF) and high stroke risk. DATA SOURCES/STUDY
SETTING: Veterans Health Administration (VHA) Corporate Data Warehouse (CDW) linked with Medicare claims 2011-2015. STUDY
DESIGN: We identified 6619 elderly, high stroke-risk patients with a new episode of AF initially diagnosed in the VHA during fiscal years 2012-2015. We used logistic regression to estimate marginal effects of associations between patient characteristics and OAC initiation within 90 days of the first AF episode. DATA EXTRACTION
METHODS: We identified OACs using generic drug names. We calculated comorbidities and risk scores using diagnosis codes from 1 year of baseline data. PRINCIPAL
FINDINGS: Overall, 66.5% of Medicare-eligible Veterans with AF at high risk of stroke initiated an OAC within 90 days. We found lower initiation rates for patients enrolled in Medicare Part D and those ineligible for drug co-payment subsidies. OAC initiation rates increased during the study among VHA-reliant patients but not among dual VHA-Part D enrollees.
CONCLUSIONS: One-third of elderly Veterans at risk of stroke are not receiving recommended therapy. Increased coordination between Medicare and VHA providers may lead to improvements in anticoagulation quality and stroke prevention. © Health Research and Educational Trust.

Entities:  

Keywords:  VA Health Care System; chronic disease; medical decision-making; pharmaceuticals: prescribing/use/costs

Mesh:

Substances:

Year:  2018        PMID: 30417341      PMCID: PMC6338291          DOI: 10.1111/1475-6773.13079

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  41 in total

1.  Pharmacy Use in the First Year of the Veterans Choice Program: A Mixed-methods Evaluation.

Authors:  Walid F Gellad; Francesca E Cunningham; Chester B Good; Joshua M Thorpe; Carolyn T Thorpe; Brandi Bair; KatieLynn Roman; Susan L Zickmund
Journal:  Med Care       Date:  2017-07       Impact factor: 2.983

2.  Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population.

Authors:  Susan Colilla; Ann Crow; William Petkun; Daniel E Singer; Teresa Simon; Xianchen Liu
Journal:  Am J Cardiol       Date:  2013-07-04       Impact factor: 2.778

3.  Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.

Authors:  Joshua Buck; Peter Kaboli; Brian F Gage; Peter Cram; Mary S Vaughan Sarrazin
Journal:  Am Heart J       Date:  2016-06-21       Impact factor: 4.749

4.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

Authors:  Gregory Y H Lip; Robby Nieuwlaat; Ron Pisters; Deirdre A Lane; Harry J G M Crijns
Journal:  Chest       Date:  2009-09-17       Impact factor: 9.410

5.  Impact on Outcomes of Changing Treatment Guideline Recommendations for Stroke Prevention in Atrial Fibrillation: A Nationwide Cohort Study.

Authors:  Tze-Fan Chao; Chia-Jen Liu; Ta-Chuan Tuan; Kang-Ling Wang; Yenn-Jiang Lin; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Tzeng-Ji Chen; Chern-En Chiang; Ming-Hsiung Hsieh; Gregory Y H Lip; Shih-Ann Chen
Journal:  Mayo Clin Proc       Date:  2016-04-08       Impact factor: 7.616

6.  Anticoagulant use for atrial fibrillation in the elderly.

Authors:  Mary T Brophy; Kerri E Snyder; Stephan Gaehde; Charlene Ives; David Gagnon; Louis D Fiore
Journal:  J Am Geriatr Soc       Date:  2004-07       Impact factor: 5.562

7.  Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study.

Authors:  Staffan Björck; Bo Palaszewski; Leif Friberg; Lennart Bergfeldt
Journal:  Stroke       Date:  2013-08-27       Impact factor: 7.914

8.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

9.  The use of warfarin in veterans with atrial fibrillation.

Authors:  Dawn M Bravata; Karen Rosenbeck; Sue Kancir; Lawrence M Brass
Journal:  BMC Cardiovasc Disord       Date:  2004-10-21       Impact factor: 2.298

10.  Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation.

Authors:  Xiaoxi Yao; Neena S Abraham; G Caleb Alexander; William Crown; Victor M Montori; Lindsey R Sangaralingham; Bernard J Gersh; Nilay D Shah; Peter A Noseworthy
Journal:  J Am Heart Assoc       Date:  2016-02-23       Impact factor: 5.501

View more
  4 in total

1.  Guideline-concordant initiation of oral anticoagulant therapy for stroke prevention in older veterans with atrial fibrillation eligible for Medicare Part D.

Authors:  Nicolae Done; Amanda M Roy; Yingzhe Yuan; Steven D Pizer; Adam J Rose; Julia C Prentice
Journal:  Health Serv Res       Date:  2018-11-11       Impact factor: 3.402

2.  Association of Neighborhood Disadvantage and Anticoagulation for Patients with Atrial Fibrillation in the Veterans Health Administration: the REACH-AF Study.

Authors:  Annie McDermott; Nadejda Kim; Leslie R M Hausmann; Jared W Magnani; Chester B Good; Terrence M A Litam; Maria K Mor; Toluwa D Omole; Walid F Gellad; Michael J Fine; Utibe R Essien
Journal:  J Gen Intern Med       Date:  2022-09-23       Impact factor: 6.473

3.  Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation.

Authors:  Marina Serper; Ethan M Weinberg; Jordana B Cohen; Peter P Reese; Tamar H Taddei; David E Kaplan
Journal:  Hepatology       Date:  2020-11-09       Impact factor: 17.425

4.  Disparities in Anticoagulant Therapy Initiation for Incident Atrial Fibrillation by Race/Ethnicity Among Patients in the Veterans Health Administration System.

Authors:  Utibe R Essien; Nadejda Kim; Leslie R M Hausmann; Maria K Mor; Chester B Good; Jared W Magnani; Terrence M A Litam; Walid F Gellad; Michael J Fine
Journal:  JAMA Netw Open       Date:  2021-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.